Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan

Oncology Nursing Forum
Vicki L FisherSuzanne L Nuss

Abstract

To provide clinical insights into dosing and administration of IV busulfan, a conditioning agent for hematopoietic stem cell transplantation (HSCT). Review of published literature related to busulfan pretransplant conditioning using MEDLINE. Meeting abstracts, investigational protocols, and pharmaceutical manufacturers' package inserts also were reviewed. Busulfan is an effective myeloablative conditioning agent for HSCT. The IV formulation increases dose assurance and the ability to target a therapeutic window. Therapeutic drug monitoring ensures that targeted blood levels are achieved, especially in children, thereby preventing underdosing, which can lead to disease progression or rejection, as well as overdosing, which can cause an increased risk of toxic side effects. IV busulfan is a convenient, safe, and effective conditioning agent used in HSCT that has a predictable pharmacokinetic profile. An understanding of the pharmacokinetic principles underlying the relationship between the therapeutic window for busulfan and optimal HSCT outcomes will facilitate proper dosing and administration of IV busulfan.

References

Jan 1, 1991·Cancer Chemotherapy and Pharmacology·M HassanI Wallin
Jan 1, 1989·European Journal of Clinical Pharmacology·M HassanB Simonsson
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·G VassalJ Lemerle
Mar 1, 1996·International Journal of Radiation Oncology, Biology, Physics·R H ChouW M Wara
May 1, 1996·Archives of Disease in Childhood·A CohenC Romano
Aug 1, 1996·Leukemia & Lymphoma·M HassanP Ljungman
Oct 19, 1999·Medical Oncology·M Hassan
Sep 8, 2000·Clinical Pharmacokinetics·J S McCuneJ T Slattery
Jan 10, 2001·Bone Marrow Transplantation·L L DupuisE F Saunders
Sep 12, 2001·Bone Marrow Transplantation·S I Bearman
Jan 10, 2002·Bone Marrow Transplantation·A M BolingerM J Cowan
Feb 9, 2002·Pediatric Hematology and Oncology·N KrivoyJ M Rowe
Oct 11, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Louise B Grochow
Oct 11, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J A RussellB S Andersson
Oct 11, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Borje S AnderssonRichard E Champlin

❮ Previous
Next ❯

Citations

Jul 21, 2009·Expert Opinion on Drug Metabolism & Toxicology·Jeannine S McCune, Leona A Holmberg
Jun 14, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jianlin QiaoKailin Xu
Aug 11, 2012·Clinical Drug Investigation·Lesley J ScottKatherine A Lyseng-Williamson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Bone Marrow Transplantation
P MorandiV Fosser
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Andrew S ArtzKoen van Besien
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Deborah SiegalVikas Gupta
© 2021 Meta ULC. All rights reserved